These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15584862)

  • 61. Regulation of translation initiation by FRAP/mTOR.
    Gingras AC; Raught B; Sonenberg N
    Genes Dev; 2001 Apr; 15(7):807-26. PubMed ID: 11297505
    [No Abstract]   [Full Text] [Related]  

  • 62. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
    Mita M; Sankhala K; Abdel-Karim I; Mita A; Giles F
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1947-54. PubMed ID: 19012509
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease.
    Santos RX; Correia SC; Cardoso S; Carvalho C; Santos MS; Moreira PI
    J Neurochem; 2011 Jun; 117(6):927-36. PubMed ID: 21447003
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
    Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
    Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation.
    Wang Y; Bai Y; Qin L; Zhang P; Yi T; Teesdale SA; Zhao L; Pober JS; Tellides G
    Circ Res; 2007 Sep; 101(6):560-9. PubMed ID: 17656678
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin.
    Braun-Dullaeus RC; Mann MJ; Seay U; Zhang L; von Der Leyen HE; Morris RE; Dzau VJ
    Arterioscler Thromb Vasc Biol; 2001 Jul; 21(7):1152-8. PubMed ID: 11451744
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Recent patents and patent applications relating to mTOR pathway.
    Liu X; Yue Z
    Recent Pat DNA Gene Seq; 2009; 3(1):44-52. PubMed ID: 19149738
    [TBL] [Abstract][Full Text] [Related]  

  • 70. mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?
    Kwiatkowski DJ; Wagle N
    EBioMedicine; 2015 Jan; 2(1):2-4. PubMed ID: 26137524
    [No Abstract]   [Full Text] [Related]  

  • 71. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
    Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
    Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM
    Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
    [No Abstract]   [Full Text] [Related]  

  • 73. The TOR kinases link nutrient sensing to cell growth.
    Rohde J; Heitman J; Cardenas ME
    J Biol Chem; 2001 Mar; 276(13):9583-6. PubMed ID: 11266435
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
    Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling.
    Chen J; Fang Y
    Biochem Pharmacol; 2002 Oct; 64(7):1071-7. PubMed ID: 12234610
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sirolimus: its discovery, biological properties, and mechanism of action.
    Sehgal SN
    Transplant Proc; 2003 May; 35(3 Suppl):7S-14S. PubMed ID: 12742462
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rapamycin: signaling in vascular smooth muscle.
    Marks AR
    Transplant Proc; 2003 May; 35(3 Suppl):231S-233S. PubMed ID: 12742501
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition.
    Blagosklonny MV
    Cell Cycle; 2006 Sep; 5(18):2087-102. PubMed ID: 17012837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.